Page last updated: 2024-11-12

cysteinyldopa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cysteinyldopa: Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14178745
CHEBI ID81392
MeSH IDM0005549

Synonyms (19)

Synonym
cysteinyldopa
19641-92-0
C17935
5-s-cysteinyl-dopa
l-tyrosine, 3-((2-amino-2-carboxyethyl)thio)-5-hydroxy-, (r)-
6i8hv27iut ,
unii-6i8hv27iut
BRD-K87166736-001-01-9
CHEBI:81392
Q60998702
(2s)-2-amino-3-(3-((2r)-2-amino-3-hydroxy-3-oxo-propyl)sulfanyl-4,5-dihydroxy-phenyl)propanoic acid
5-s-l-cysteinyl-l-dopa
alanine, 3-(3-((2-amino-2-carboxyethyl)thio)-4,5-dihydroxyphenyl)-, l-
5-s-cysteaminyldopamine
3-(((2r)-2-amino-2-carboxyethyl)thio)-5-hydroxy-l-tyrosine
l-tyrosine, 3-(((2r)-2-amino-2-carboxyethyl)thio)-5-hydroxy-
(2s)-2-amino-3-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-4,5-dihydroxyphenyl]propanoic acid
s-(5-((s)-2-amino-2-carboxyethyl)-2,3-dihydroxyphenyl)-l-cysteine
DTXSID301027547

Research Excerpts

Overview

5-S-cysteinyldopa is a well-known pigment intermediate. Analysis of its plasma concentration is interesting for the early diagnosis, as well as for evaluation of treatment and follow-up of malignant melanoma.

ExcerptReferenceRelevance
"5-S-Cysteinyldopa (5-S-CD) is a precursor of pheomelanin. "( Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi, T; Boldizsár, M; Gergye, M; Gilde, K; Kremmer, T; Ottó, S, 2003
)
0.88
"5-S-cysteinyldopa is a precursor of pheomelanin. "( Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi, T; Boldizsár, M; Gergye, M; Gilde, K; Kremmer, T; Ottó, S, 2002
)
1.12
"5-S-cysteinyldopa is a well-known pigment intermediate and analysis of its plasma concentration is interesting for the early diagnosis, as well as for evaluation of treatment and follow-up of malignant melanoma. "( Development of a mass spectrometry method for the determination of a melanoma biomarker, 5-S-cysteinyldopa, in human plasma using solid phase extraction for sample clean-up.
Chiap, P; Crommen, J; de Tullio, P; Fillet, M; Hubert, P; Martin, GB; Martin, Y; Paquet, P; Pierard, G; Rozet, E, 2007
)
1.12
"5-S-cysteinyldopa was found to be a substrate for tyrosinase, but our results suggests that a self-catalysed oxidation induced by enzymatically formed 5-S-cysteinyl dopaquinone also takes place."( 5-S-cysteinyldopa as a substrate for tyrosinase.
Hansson, C; Rorsman, H; Rosengren, E, 1980
)
1.3
"5-S-cysteinyldopa (5-S-DC) is a precursor of melanin. "( Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
Bánfalvi, T; Beczássy, E; Boldizsár, M; Fejös, Z; Gilde, K; Horváth, B; Kremmer, T; Liszkay, G, 2000
)
1.16
"5-S-cysteinyldopa is a precursor of melanin. "( Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
Bánfalvi, T; Boldizsár, M; Gilde, K; Kremmer, T, 2002
)
1.16
"Cysteinyldopa is an intermediate in the biosynthesis of the red-brown phaeomelanin."( The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
Nixon, PF, 1978
)
1.29

Effects

5-S-cysteinyldopa has been described as a tumour marker for the detection of human metastatic melanoma.

ExcerptReferenceRelevance
"5-S-Cysteinyldopa (5-S-CD) has been used as a biochemical marker of melanoma progression. "( Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Furue, M; Hatta, N; Ito, S; Kageshita, T; Kiyohara, Y; Naito, A; Nakayama, J; Ono, T; Saida, T; Takata, M; Tsuchida, T; Uhara, H; Wakamatsu, K; Yamamoto, A; Yamazaki, N, 2002
)
1.21
"5-S-cysteinyldopa (5-S-CD) has been described as a tumour marker for the detection of human metastatic melanoma. "( Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
Arndt, R; Christophers, E; Hartleb, J; Hauschild, A; Kromminga, A; Meyer, T; Stockfleth, E, 2002
)
1.17
"5-S-Cysteinyldopa (5-S-CD) has been used as a biochemical marker of melanoma progression. "( Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Ito, S; Kageshita, T; Naito, A; Wakamatsu, K; Yokochi, M, 2003
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
catecholamine4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (262)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990141 (53.82)18.7374
1990's54 (20.61)18.2507
2000's51 (19.47)29.6817
2010's12 (4.58)24.3611
2020's4 (1.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.95 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (1.87%)5.53%
Reviews10 (3.73%)6.00%
Case Studies19 (7.09%)4.05%
Observational1 (0.37%)0.25%
Other233 (86.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]